


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On December 5, 2005

TOWNSEND and TOWNSEND and CREW LLP

By:

  
Jo Ann Honcik Dallara



**PATENT**  
Attorney Docket No.: 15280W-002100US  
Client Ref. No.: E-286-1998/1-US-06  
Customer No.: 45115

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

BRENNEMAN *et al.*

Application No.: 10/049,587

Filed: February 12, 2002

For: ORALLY ACTIVE PEPTIDES  
THAT PREVENT CELL DAMAGE AND  
DEATH

Confirmation No. 9701

Examiner: Standley, Steven H.

Art Unit: 1649

**COMMUNICATION UNDER**

**37 C.F.R. §§ 1.821-1.825**

**AND**

**AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed November 4, 2005, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification as follows.

Appl. No. 10/049,587  
Amdt. dated December 5, 2005  
Reply to Office Communication of November 4, 2005

PATENT

**Amendments to the Specification** begin on page 3 of this paper.

**Remarks** begin on page 10 of this paper.